As the 1970s progressed, home therapy with Factor 9 concentrates became a feature of the treatment of people with Haemophilia B Read more about As the 1970s progressed, home therapy with Factor 9 concentrates became a feature of the treatment of people with Haemophilia B
Part II Licensing granted authority for products including 'dried human antihemophilic fraction' and 'dried human factor IX fraction' Read more about Part II Licensing granted authority for products including 'dried human antihemophilic fraction' and 'dried human factor IX fraction'
Table provided Protein Fraction Centre licences updates and renewals Read more about Table provided Protein Fraction Centre licences updates and renewals
Authority was given for the grant of a product licence for Proplex Factor IX Complex Read more about Authority was given for the grant of a product licence for Proplex Factor IX Complex
Proplex Factor IX Complex (Human) was granted a product licence Read more about Proplex Factor IX Complex (Human) was granted a product licence
An application for renewal of product licence Proplex Factor IX Complex was made from Travenol Laboratories Read more about An application for renewal of product licence Proplex Factor IX Complex was made from Travenol Laboratories
It was stated that the "The biological roles of Factors 8 and 9 are closely related...and so the clinical picture that is caused by these deficiencies is near identical." Read more about It was stated that the "The biological roles of Factors 8 and 9 are closely related...and so the clinical picture that is caused by these deficiencies is near identical."
Prior to 1952 patients were categorised under a generic diagnosis of haemophilia, but by 1952 Haemophilia B could be identified separately from Haemophilia A. Read more about Prior to 1952 patients were categorised under a generic diagnosis of haemophilia, but by 1952 Haemophilia B could be identified separately from Haemophilia A.
Haemophilia B was referred to "Christmas disease" after the name of the first patient whose condition was examined in detail. Read more about Haemophilia B was referred to "Christmas disease" after the name of the first patient whose condition was examined in detail.
Dr Mitchell argued "recurrent treatment with blood products is hazardous... The best approach seems to us to be a treatment policy" designed to reduce all the risks associated with blood products and is tailored to the needs of individual patients. Read more about Dr Mitchell argued "recurrent treatment with blood products is hazardous... The best approach seems to us to be a treatment policy" designed to reduce all the risks associated with blood products and is tailored to the needs of individual patients.